This GLP-1 Agonist Medications Chart outlines the latest GLP-1 medications approved by the FDA for diabetes treatment and the differences and similarities between them. Print out this chart and post in your office as a handy reference for your staff and patients alike.
The chart is in PDF format. Use this link to download: GLP-1 Agonist Medications Chart (updated November 1, 2018)
GLP-1 Receptor Agonists for Type 2 Diabetes Currently Available in the U.S.
GLP-1 agonists are a class of antidiabetic agents that mimic the actions of the glucagon-like peptide. GLP-1 is one of several naturally occurring incretin compounds that affect the body after they are released from the gut during digestion. By binding and activate GLP-1 receptors, GLP-1 agonists, and endogenous GLP-1 are capable to reduce blood glucose levels helping T2DM patients to reach a glycemic control. These antidiabetic agents increase the glucose-dependent secretion of insulin from functioning beta cells, decrease glucagon release after meals, decrease hepatic glucose production, delayed gastric emptying, suppress the appetite and promotes beta cell proliferation. After the launched of exenatide (Byetta) in 2005 newer formulations have been released with the allowing for longer half life’s and better side effect profiles. Soliqua and Xultophy are two combination pen devices that deliver a GLP-1 RA and basal insulin simultaneously allowing a robust reduction of HbA1c when compare to insulin alone. The attached chart presents a list with the different GLP-1 receptor agonist available in the U.S. and some of their featured characteristics.